Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
Completed
- Conditions
- Type 2 DiabetesHypertensionDyslipidemiaDiabetic Nephropathy
- Registration Number
- NCT00419484
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.
- Detailed Description
Primary composite endpoints:
Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine)
Secondary endpoints:
urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- type 2 diabetes HbA1c: more than 7% and less than 9%
Exclusion Criteria
- insulin treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pioglitazone's cardiovascular benefits in type 2 diabetes patients?
How does pioglitazone compare to other thiazolidinediones in reducing macrovascular complications in diabetic populations?
Which biomarkers correlate with improved renal outcomes in Japanese patients treated with pioglitazone for type 2 diabetes?
What are the long-term adverse event profiles of pioglitazone in patients with concurrent hypertension and hyperlipidemia?
How do PPAR-gamma agonists like pioglitazone influence endothelial function and atherosclerosis progression in type 2 diabetes?
Trial Locations
- Locations (1)
Dokkyo Medical University, Koshigaya Hospital
🇯🇵Koshigaya, Saitama, Japan
Dokkyo Medical University, Koshigaya Hospital🇯🇵Koshigaya, Saitama, Japan